INTEGRILIN 100ML/75MG INJ

Eptifibatide, a 75MG injection, is a potent and highly selective antiplatelet agent that works by inhibiting the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor on the surface of platelets. This receptor plays a crucial role in the final common pathway of platelet aggregation. When activated, it allows fibrinogen and other adhesive proteins to bind to the platelets, forming a cross-linked network that stabilizes the platelet plug and promotes thrombus formation. Eptifibatide, a cyclic heptapeptide, binds reversibly to the GPIIb/IIIa receptor, blocking its interaction with fibrinogen and other adhesive proteins. By preventing the binding of these proteins, eptifibatide effectively inhibits platelet aggregation, thereby reducing the risk of thrombus formation and subsequent cardiovascular events. This mechanism of action makes eptifibatide a valuable tool in managing acute coronary syndromes and preventing thrombotic complications during certain medical procedures.

Eptifibatide 75MG

Antiplatelet

Injection

The following are the uses of Eptifibatide 75MG Injection:

• Used for preventing blood clots in patients with unstable angina or those undergoing angioplasty
• Used for rapid and effective platelet inhibition to prevent thrombotic events during coronary angioplasty
• Used to treat patients with acute coronary syndrome to reduce the risk of heart attack
• Used for managing patients with high-risk coronary artery disease
• Used for preventing ischemic complications in patients with unstable conditions
• Used for improving blood flow and reducing the risk of cardiovascular events
• Used in emergency situations to prevent life-threatening blood clots

In the case of an overdose of Eptifibatide 75MG Injection, it is important to seek medical attention promptly. Overdose symptoms may include prolonged bleeding, easy bruising, or nosebleeds. The severity of symptoms can vary based on the amount ingested and individual factors. If you suspect an overdose, contact a healthcare professional or poison control center for guidance. They can provide specific recommendations based on the circumstances of the overdose.

In the case of a missed dose of Eptifibatide 75MG Injection, it is important to administer the medication as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to make up for a missed one, as this may increase the risk of side effects. If you have missed multiple doses, contact your healthcare provider for guidance on how to proceed and to ensure the treatment remains effective.

To administer Eptifibatide 75MG Injection, carefully insert the needle into the vial, withdraw the prescribed dose using a syringe, and inject it intravenously, ensuring proper dosage accuracy and following the administration guidelines provided by your healthcare professional.

Following are the conditions/situations when Eptifibatide 75MG Injection should not be used:

• Should not be used in patients with a known allergy or hypersensitivity to Eptifibatide or any of its components.
• Contraindicated in patients with active bleeding or bleeding disorders.
• Not recommended for patients with a history of stroke or intracranial hemorrhage.
• Should not be used in individuals with severe uncontrolled hypertension.
• Contraindicated during pregnancy as it may cause harm to the fetus.
• Not suitable for patients with severe liver or kidney disease.
• Avoid using Eptifibatide if you have recently had major surgery or a severe traumatic injury.

The side effects of Eptifibatide 75MG Injection may include:

• Bleeding at the injection site
• Bruising
• Allergic reactions (such as rash, itching, or hives)
• Nausea and vomiting
• Headache
• Increased bleeding time
• Thrombocytopenia (low platelet count)
• Back pain

Following are the precautions and warnings for Eptifibatide 75MG Injection:

• It should be administered under medical supervision and only by trained healthcare professionals experienced in managing acute coronary syndromes.
• Not recommended for individuals with active internal bleeding or a history of bleeding disorders, as it can increase the risk of bleeding complications.
• Caution is advised in patients with severe kidney disease, as dosage adjustments may be necessary to prevent potential complications.
• Patients should be monitored for signs of thrombocytopenia (low platelet count) during treatment, and the therapy should be discontinued if platelet count decreases significantly.
• Eptifibatide should be used with caution in patients with hypertension, as it may cause an increase in blood pressure.
• It is recommended to monitor liver function tests during prolonged therapy, as rare cases of liver dysfunction have been reported.
• Patients should be advised to seek immediate medical attention if they experience any signs of allergic reactions, such as rash, itching, swelling, or difficulty breathing.
• The use of Eptifibatide in pregnant and breastfeeding women should be carefully considered, as there is limited data available regarding its safety in these populations.

Following are the drug interactions for Eptifibatide 75MG Injection:

• Thrombolytic agents like alteplase, reteplase, and streptokinase can increase the risk of bleeding when used with eptifibatide. Close monitoring is required.
• Anticoagulants such as heparin and warfarin may enhance the risk of bleeding, and regular coagulation tests are advised.
• NSAIDs (e.g., ibuprofen, naproxen) may further elevate bleeding risks, and caution should be exercised.
• The combination of eptifibatide with other antiplatelet drugs like clopidogrel or aspirin can potentiate bleeding tendencies.
• Drugs that impact renal function may influence eptifibatide clearance, requiring dosage adjustments.
• When used with potent CYP3A4 inhibitors, eptifibatide levels may rise, necessitating monitoring and dosage adjustments.
• Some antibiotics (e.g., rifampin) can induce CYP3A4, reducing eptifibatide effectiveness.

Following are the food interactions to be aware of with Eptifibatide 75MG Injection:

• Avoid consuming alcohol during treatment, as it may increase the risk of bleeding and affect platelet function.
• Grapefruit and its juice should be avoided as they can interfere with the metabolism of the medication, potentially increasing its levels in the body.
• Avoid foods rich in vitamin K like spinach, kale, and broccoli, as they can counteract the medication's anti-clotting effects.
• Limit caffeine intake from coffee, tea, and energy drinks, as it may enhance the medication's effects on blood pressure.
• Avoid high-fat meals as they may delay the absorption of Eptifibatide.
• Do not consume herbal supplements like Ginkgo Biloba and garlic supplements, as they can increase the risk of bleeding.
• Always stay hydrated by drinking enough water, but avoid excessive fluid intake, as it may affect blood volume and pressure.
• Consult your healthcare provider for specific dietary recommendations tailored to your medical condition.

Eptifibatide 75MG Injection should be stored in a controlled environment, specifically at room temperature between 20-25°C (68-77°F). Protect the injection from light and keep it in its original packaging until use. It is crucial to maintain a clean and dry storage area, ensuring the medication is not exposed to moisture or any potential contaminants. When disposing of unused or expired Eptifibatide, do not throw it in the trash or pour it down the drain. Contact your healthcare provider or pharmacist for guidance on safe disposal methods to minimize environmental impact. Keep this medication out of children's reach to prevent accidental exposure, and always exercise caution when handling and storing Eptifibatide to maintain its integrity and effectiveness.

Following are the quick tips for Eptifibatide 75MG Injection:

• Ensure you receive this injection under medical supervision as prescribed.
• Inform your doctor about your medical history, especially recent surgeries or bleeding issues.
• Let your healthcare provider know if you are pregnant, breastfeeding, or planning a pregnancy.
• Avoid activities that may cause bruising or bleeding during treatment.
• Report any unusual bleeding, easy bruising, or prolonged bleeding to your doctor promptly.
• Do not reuse or share needles/syringes to prevent infections.
• Store the injection as directed, away from heat and light.
• In case of any adverse reactions, seek immediate medical attention.